Indevus will pay $30 million for US rights to Schering's Nebido, a testosterone-replacement injection that lasts for three months. The money includes up-front, regulatory milestone, and commercialization milestone payments, including $7.5 million up-front and $5 million upon approval of the product. Nebido was recently approved and launched in Europe "Our acquisition of rights to Nebido in the US is a major step in the execution of our corporate strategy. Leveraging and building on our existing franchise in urology has been our highest priority since the launch of Sanctura," said Glenn L. Cooper, MD, chairman, president and CEO of Indevus.
- read this press release for more